Valion Bio Inc (NASDAQ:VBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Valion Bio Inc (VBIO)
Valion Bio Inc (NASDAQ:VBIO) has a market capitalization of $1.87 Million ($1.87 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30178 globally and #6141 in its home market, demonstrating a -23.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Valion Bio Inc's stock price $2.11 by its total outstanding shares 887589 (887.59K). Also see Valion Bio Inc asset portfolio for a full breakdown of the balance sheet.
Valion Bio Inc Market Cap History: 2026 to 2026
Valion Bio Inc's market capitalization history from 2026 to 2026. Data shows growth from $1.87 Million to $1.87 Million (0.00% CAGR). Also see VBIO cash flow metrics for how efficiently the company converts equity into cash flow.
Valion Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Valion Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check VBIO stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VBIO by Market Capitalization
Companies near Valion Bio Inc in the global market cap rankings as of September 17, 2026. Review how tangible is Valion Bio Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Valion Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Valion Bio Inc Historical Marketcap From 2026 to 2026
Between 2026 and today, Valion Bio Inc's market cap moved from $1.87 Million to $ 1.87 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.87 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Valion Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.87 Million USD |
| MoneyControl | $1.87 Million USD |
| MarketWatch | $1.87 Million USD |
| marketcap.company | $1.87 Million USD |
| Reuters | $1.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more